Exelixis
EXEL
#1644
Rank
A$15.98 B
Marketcap
$58.01
Share price
0.98%
Change (1 day)
61.61%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.44. In 2022 the company made an earnings per share (EPS) of $0.89 a decrease over its 2021 EPS that were of $1.16.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.43-51.79%
2022$0.89-22.97%
2021$1.16100%
2020$0.58-65.09%
2019$1.66-53.91%
2018$3.59333.96%
2017$0.83-260.61%
2016-$0.52-58.75%
2015-$1.25-42.45%
2014-$2.175.3%
2013-$2.0643.48%
2012-$1.44-264.29%
2011$0.87-165.88%
2010-$1.33-32.54%
2009-$1.97-17.65%
2008-$2.3975.86%
2007-$1.36-25.64%
2006-$1.838.33%
2005-$1.69-42.86%
2004-$2.9530.34%
2003-$2.26-5.23%
2002-$2.39-0.65%
2001-$2.41-51.88%
2000-$5.00

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.47 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.97 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.85 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.20 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.10 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.00 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.90 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$15.62-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.31-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA